Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. C. Dobler, G. B. Marks (Sydney, Australia). Adverse events during treatment for latent tuberculosis infection. Eur Respir J 2011; 38: Suppl. 55, 4404

Member's Comments

No comment yet.

Related content which might interest you: Treatment of latent tuberculosis infection: completion rates and adverse effects Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Adverse reactions to the tuberculosis treatment Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Adverse effects of moxifloxacin during tuberculosis treatment Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Adverse reactions of tuberculosis treatment in pacients with and without associated digestive disorders Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019 Year: 2019 Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis. Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter? Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006